Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex

Int J Neuropsychopharmacol. 2008 Aug;11(5):591-5. doi: 10.1017/S1461145708009061.

Abstract

Repeated antipsychotic treatment may produce adaptive changes ranging from cytoarchitectural rearrangements to synaptic modifications that might contribute to clinical improvement. We performed a prolonged treatment (2 wk) with the first-generation antipsychotic (FGA) haloperidol (1 mg/kg) and the second-generation antipsychotic (SGA) olanzapine (2 mg/kg twice daily) and analysed the expression of the polysialylated form of neural cell adhesion molecule (PSA-NCAM) in rat hippocampus and prefrontal cortex via immunohistochemistry. We found a regional- and drug-selective increase of PSA-NCAM expression in prefrontal cortex of olanzapine-treated rats with no effects in hippocampus; conversely, haloperidol did not produce a change in either brain region. Our findings reveal a possible role for PSA-NCAM in the mechanism of action of the SGA olanzapine adding complexity as well as specificity to the molecular changes set in motion by this drug.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Benzodiazepines / pharmacology*
  • Cell Count / methods
  • Dopamine Antagonists / pharmacology*
  • Haloperidol / pharmacology*
  • Male
  • Neural Cell Adhesion Molecule L1 / metabolism*
  • Olanzapine
  • Prefrontal Cortex / drug effects*
  • Prefrontal Cortex / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Sialic Acids / metabolism*

Substances

  • Dopamine Antagonists
  • Neural Cell Adhesion Molecule L1
  • Serotonin Uptake Inhibitors
  • Sialic Acids
  • polysialyl neural cell adhesion molecule
  • Benzodiazepines
  • Haloperidol
  • Olanzapine